NHRF Innovation

NHRF has become a key player both at the National and International levels in the development of new scientific knowledge. The dual scientific identity of NHRF due to the successful coexistence of Humanities and Natural Sciences Institutes affords a unique advantage and achievement at the national level and increases its competitiveness abroad.

The Institute of Historical Research (IHR) is at international level, one of the most important places for the study of the Greek archaeology and history (ancient, medieval and modern) and, at the same time, a unique infrastructure of national importance. The two "Natural Sciences" Institutes have excelled in their individual fields of study whereas, in the framework of the strategic policy of the Foundation, they optimize the potentials for synergies due to their spatial and scientific proximity. In addition, the human capital as well as the logistics infrastructures for the common development of innovative interdisciplinary basic research actions and applications is present as well.

NHRF's main priorities for the following years, include scientific excellence at international level, enhancement of its research and educational mission and effective linking of Greek economy and society.


Innovation, Technology Transfer & Entrepreneurship

Innovation management, promotion of collaboration and provision of services towards industry, enterprises and the wider public sector, constitute a fundamental issue for the development of the NHRF.
This will be accomplished through the following actions:

  • Mapping of the services and the products that the NHRF can provide
  • Identification of potential users of the services and products of the NHRF - mapping of the potential market
  • Focus on fields that lie at the forefront of science, especially on nano-materials, medicine, environment, health, photonics and biotechnology applications as well as on innovative technological applications in the broader field of historical sciences and culture
  • Adoption of policies to attract and develop human resources
  • Enhancement of closer partnerships through program agreements with private and public entities, with emphasis on the areas of health, environment, culture and Greek scientific digital content
  • Modernization and expansion of assets for Research Institutes and Libraries for a further development in e- content, repositories and electronic reading rooms
  • Strengthening the competitiveness of the Foundation and the ability to ensure financing especially from the EU and International Organizations
  • Support of researchers in their collaboration with other research institutes or industry
  • Support of researchers regarding issues of Intellectual Property, Inventions, Entrepreneurship, technology transfer etc.
  • Networking with other organizations of technology transfer in Europe
  • Promotion of the research and overall activities of the NHRF to the general public as well as to other research organizations in Europe


NHRF Spin-off Companies

e-NIOS Applications S.A. (e-Noesis Inspired Operational Systems, www.e-nios.com) is a NHRF spin-off company specialized in Bioinformatics, recently founded by the members of the Metabolic Engineering and Bioinformatics Group, Aristotle Chatziioannou (Research Associate Professor), Eleftherios Pilalis and Ioannis Valavanis (post-doctoral researchers). The expertise of the e-NIOS team is inherently multidisciplinary, encompassing extensive research experience in the fields of Bioinformatics, Genomics, Artificial Intelligence, Data Mining, Operational Research and Decision Support Systems.

Read more


ResQ Biotech (www.resqbiotech.com) is a spin-off company of the Institute of Chemical Biology of the National Hellenic Research Foundation established in 2019 at the Patras Science Park. It is a platform technology/drug discovery company targeting diseases caused by problematic protein folding and aggregation (Alzheimer’s disease, amyotrophic lateral sclerosis, cancer, systemic amyloidosis etc.). Its proprietary biotechnological approach uses genetically engineered E. coli bacteria to biosynthesize billions of cyclic oligopeptides, an emerging class of therapeutic molecules, and simultaneously screen them to identify inhibitors of pathogenic protein misfolding and aggregation. ResQ Biotech aspires to become a partner of choice for every Pharma & Biotech company that is developing drugs for protein misfolding diseases and looking for new assets to expand their pipelines. It is currently raising its Seed Round of funding.

Read more